Patent details

LUC00383 Product Name: Repotrectinib et/ou ses sels et esters pharmaceutiquement acceptables

Basic Information

Publication number:
LUC00383
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP191690411
Legal Status:
Pending & Published
Application number:
LUC00383
First applicant's nationality:
Procedural language:
English

Marketing Authorization

Marketing Authorization Number:
EU/1/24/1883
Marketing Authorization Type:
Marketing Authorization Date:
14/01/2025
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
07/03/2025
First Marketing Authorization date:
14/01/2025
Grant date:
Activation date:
Publication date:
10/03/2025
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
14/01/2040
SPC Extension Expiration:
14/01/2040
Rejection date:
Withdrawal date:

Owner

From:
07/03/2025
 
 

Name:
TURNING POINT THERAPEUTICS, INC.
Address:
Route 206 and Province Line Road, NJ 08543, Princeton, , United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
07/03/2025
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

Bulletin Heading:
SPC1
Bulletin edition number:
2025/05
Publication date:
07/04/2025
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:
31/01/2035
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
07/03/2025 Summary of the product caracteristics 50
07/03/2025 Marketing authorization 3
07/03/2025 Application Form 3
10/03/2025 Outgoing Correspondence 1
10/03/2025 Publication 1
07/03/2025 MA publication 10